2010-12-01
A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients
Publication
Publication
Analytical and Bioanalytical Chemistry , Volume 398 - Issue 7-8 p. 2943- 2948
An analytical assay has been developed and validated for ultrafast and high-throughput mass spectrometric determination of pemetrexed concentrations in plasma using matrix assisted laser desorption/ionization-triple quadrupole-tandem mass spectrometry. Patient plasma samples spiked with the internal standard methotrexate were measured by multiple reaction monitoring. The detection limit was 0.4 fmol/μL, lower limit of quantification was 0.9 fmol/μL, and upper limit of quantification was 60 fmol/μL, respectively. Overall observed pemetrexed concentrations in patient samples ranged between 8.7 (1.4) and 142.7 (20.3)∈pmol/μL (SD). The newly developed mass spectrometric assay is applicable for (routine) therapeutic drug monitoring of pemetrexed concentrations in plasma from non-small cell lung cancer patients.
| Additional Metadata | |
|---|---|
| , , , , , | |
| doi.org/10.1007/s00216-010-4192-8, hdl.handle.net/1765/28616 | |
| Analytical and Bioanalytical Chemistry | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Meesters, R., Cornelissen, R., van Klaveren, R., de Jonge, R., den Boer, E., Lindemans, J., & Luider, T. (2010). A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients. Analytical and Bioanalytical Chemistry, 398(7-8), 2943–2948. doi:10.1007/s00216-010-4192-8 |
|
